Charles Schwab
EIDX

Charles Schwab’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Charles Schwab’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-71,774
Closed -$9.45M – 3548
2020
Q4 		$9.45M Sell
71,774
-21,553
-23% -$1.9M ﹤0.01% 1900
2020
Q3 		$4.72M Buy
93,327
+21,901
+31% +$984K ﹤0.01% 2089
2020
Q2 		$3.4M Buy
71,426
+24,200
+51% +$1.13M ﹤0.01% 2206
2020
Q1 		$2.31M Buy
47,226
+747
+2% +$38.1K ﹤0.01% 2218
2019
Q4 		$2.67M Buy
46,479
+3,180
+7% +$157K ﹤0.01% 2327
2019
Q3 		$1.56M Sell
43,299
-3,944
-8% -$154K ﹤0.01% 2464
2019
Q2 		$1.47M Sell
47,243
-9,361
-17% -$254K ﹤0.01% 2464
2019
Q1 		$1.33M Buy
56,604
+22,049
+64% +$354K ﹤0.01% 2474
2018
Q4 		$476K Buy
34,555
+3,021
+10% +$38.1K ﹤0.01% 2789
2018
Q3 		$315K Buy
+31,534
New +$518K ﹤0.01% 2993

Charles Schwab's EIDX Position: Q1 2021 in Review

Charles Schwab sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 71,774 shares — an estimated $9.45M sold.

Charles Schwab first reported a position in EIDX in Q3 2018 and held it in 10 quarters. The position peaked at $9.45M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Charles Schwab reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Charles Schwab sold 71,774 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $9.45M.
  • Charles Schwab first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
  • Charles Schwab's Eidos Therapeutics, Inc. Common Stock position peaked at $9.45M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Charles Schwab's 13F filing for Q1 2021, filed 17 May 2021.